Artículos de revistas
Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor β-expressing T cells
Fecha
2009Registro en:
Journal of Clinical Oncology, Volumen 27, Issue 6, 2018, Pages 945-952
0732183X
10.1200/JCO.2008.18.0794
Autor
López, Mercedes N.
Pereda, Cristian
Segal, Gabriela
Muñoz, Leonel
Aguilera, Raquel
González, Fermín E.
Escobar, Alejandro
Ginesta, Alexandra
Reyes, Diego
González, Rodrigo
Mendoza Naranjo, Ariadna
Larrondo, Milton
Compán, Alvaro
Ferrada, Carlos
Salazar Onfray, Flavio
Institución
Resumen
Purpose The aim of this work was to assess immunologic response, disease progression, and posttreatment survival of melanoma patients vaccinated with autologous dendritic cells (DCs) pulsed with a novel allogeneic cell lysate (TRIMEL) derived from three melanoma cell lines. Patients and Methods Forty-three stage IV and seven stage III patients were vaccinated four times with TRIMEL/DC vaccine. Specific delayed type IV hypersensitivity (DTH) reaction, ex vivo cytokine production, and regulatory T-cell populations were determined. Overall survival and disease progression rates were analyzed using Kaplan-Meier curves and compared with historical records. Results The overall survival for stage IV patients was 15 months. More than 60% of patients showed DTH-positive reaction against the TRIMEL. Stage IV/DTH-positive patients displayed a median survival of 33 months compared with 11 months observed for DTH-negative patients (P = .0014). All stage III treated patients were DTH positive and re